Cargando…

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany

OBJECTIVES: The aim was to evaluate the safety and effectiveness of sarilumab in RA patients after inadequate response (IR) to janus kinase inhibitors (JAKi) and tocilizumab. METHODS: The prospective, observational, 24-month single-arm PROSARA study (SARILL08661) is currently running in Germany at 9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tony, Hans-Peter, Feist, Eugen, Aries, Peer Malte, Zinke, Silke, Krüger, Klaus, Ahlers, Jonas, Albrecht, Inka, Barrionuevo, Christian, Kalus, Stefanie, Burkhardt, Harald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Concise Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824706/ https://www.ncbi.nlm.nih.gov/pubmed/35146322 http://dx.doi.org/10.1093/rap/rkac002

Ejemplares similares

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Serological Biomarkers of Joint Tissue Turnover Predict Tocilizumab Response at Baseline
por: Bay-Jensen, Anne C., et al.
Publicado: (2014)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
por: Genovese, Mark C, et al.
Publicado: (2018)

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis
por: Zeraatkar, Dena, et al.
Publicado: (2022)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
por: Wells, Alvin F., et al.
Publicado: (2019)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis
por: Peng, Jingwen, et al.
Publicado: (2021)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study
por: Gabay, Cem, et al.
Publicado: (2018)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Publicado: (2019)

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
por: Fleischmann, Roy, et al.
Publicado: (2017)

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
por: Choy, Ernest, et al.
Publicado: (2019)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2022)

Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
por: Godolphin, Peter J., et al.
Publicado: (2022)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages()
por: Swets, Maaike C., et al.
Publicado: (2023)

Sarilumab: Cytomegalovirus colitis: case report
Publicado: (2020)

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Sarilumab: Perforated duodenal ulcer: case report
Publicado: (2021)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
por: Boyapati, Anita, et al.
Publicado: (2016)

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

The effects of microgravity on differentiation and cell growth in stem cells and cancer stem cells
por: Grimm, Daniela, et al.
Publicado: (2020)

Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
por: Muszbek, Noemi, et al.
Publicado: (2019)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
por: Russo, R, et al.
Publicado: (2011)

Defining new clinically derived criteria for high disease activity in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study
por: Backström, Maria, et al.
Publicado: (2018)

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
por: Taylor, Peter C, et al.
Publicado: (2023)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

Sarilumab use in severe SARS-CoV-2 pneumonia
por: Gremese, Elisa, et al.
Publicado: (2020)

Sarilumab: Thrombocytopenia during an off-label use: case report
Publicado: (2020)

Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
por: Chamlagain, Rajan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_06h0lr8h17ssp8i1thfu74rjj9